In addition, we also analyzed the gene expression data from a second cohort of matched tumor samples of 8 melanoma patients obtained prior to and during treatment with the BRAF inhibitors dabrafenib or vemurafenib alone or in combination with the MEKi trametinib (GSE99898) (Fig. 2B). Here, BRAF is linked to melanoma.